Showing results (361-370 of 378) with videos related to

Sort By:
Pageof 38
The Lancet. Oncology|July 10, 2025
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocolSilke Gillessen, Laura Murphy, Nicholas D James, et al.
Nature Genetics|February 12, 2008
Multiple newly identified loci associated with prostate cancer susceptibilityRosalind A Eeles, Zsofia Kote-Jarai, Graham G Giles, et al.
The Lancet. Oncology|December 7, 2019
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trialJoaquin Mateo, Nuria Porta, Diletta Bianchini, et al.
Cancer Discovery|June 14, 2020
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant CancersTimothy A Yap, Rebecca Kristeleit, Vasiliki Michalarea, et al.
Asian Journal of Andrology|December 4, 2008
Identification of new genetic risk factors for prostate cancerMichelle Guy, Zsofia Kote-Jarai, Graham G Giles, et al.
European Urology Oncology|June 26, 2025
PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular SubtypesPasquale Rescigno, Maria Dolores Fenor de la Maza, Holly Tovey, et al.
The Lancet. Oncology|May 4, 2023
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocolGerhardt Attard, Laura Murphy, Noel W Clarke, et al.
JNCI Cancer Spectrum|July 25, 2022
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled TrialNicholas D James, Fiona C Ingleby, Noel W Clarke, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2014
Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers InitiativeJan Bogaerts, Matthew R Sydes, Nicola Keat, et al.
Nature Reviews. Clinical Oncology|June 2, 2016
Clinical development of new drug-radiotherapy combinationsRicky A Sharma, Ruth Plummer, Julie K Stock, et al.
Pageof 38